639 related articles for article (PubMed ID: 19695683)
41. Nodular lymphocyte predominant Hodgkin lymphoma.
Lee AI; LaCasce AS
Oncologist; 2009 Jul; 14(7):739-51. PubMed ID: 19605845
[TBL] [Abstract][Full Text] [Related]
42. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?
Jordanova ES; Gorter A; Ayachi O; Prins F; Durrant LG; Kenter GG; van der Burg SH; Fleuren GJ
Clin Cancer Res; 2008 Apr; 14(7):2028-35. PubMed ID: 18381941
[TBL] [Abstract][Full Text] [Related]
43. Nodular lymphocyte predominant Hodgkin lymphoma. An immunophenotypic reappraisal based on a single-institution experience.
Uherova P; Valdez R; Ross CW; Schnitzer B; Finn WG
Am J Clin Pathol; 2003 Feb; 119(2):192-8. PubMed ID: 12579988
[TBL] [Abstract][Full Text] [Related]
44. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
Hamanishi J; Mandai M; Iwasaki M; Okazaki T; Tanaka Y; Yamaguchi K; Higuchi T; Yagi H; Takakura K; Minato N; Honjo T; Fujii S
Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3360-5. PubMed ID: 17360651
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of FoxP3 expression in peripheral T-cell lymphoma.
Bonzheim I; Geissinger E; Tinguely M; Roth S; Grieb T; Reimer P; Wilhelm M; Rosenwald A; Müller-Hermelink HK; Rüdiger T
Am J Clin Pathol; 2008 Oct; 130(4):613-9. PubMed ID: 18794055
[TBL] [Abstract][Full Text] [Related]
46. Connective tissue growth factor is expressed in malignant cells of Hodgkin lymphoma but not in other mature B-cell lymphomas.
Birgersdotter A; Baumforth KR; Wei W; Murray PG; Sjöberg J; Björkholm M; Porwit A; Ernberg I
Am J Clin Pathol; 2010 Feb; 133(2):271-80. PubMed ID: 20093237
[TBL] [Abstract][Full Text] [Related]
47. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma.
Visser L; Rutgers B; Diepstra A; van den Berg A; Sattarzadeh A
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999289
[TBL] [Abstract][Full Text] [Related]
48. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus.
Bertsias GK; Nakou M; Choulaki C; Raptopoulou A; Papadimitraki E; Goulielmos G; Kritikos H; Sidiropoulos P; Tzardi M; Kardassis D; Mamalaki C; Boumpas DT
Arthritis Rheum; 2009 Jan; 60(1):207-18. PubMed ID: 19116915
[TBL] [Abstract][Full Text] [Related]
49. Correlation between expression of cyclooxygenase-2 and the presence of CD4+ infiltrating T-lymphocyte in human primary hepatocellular carcinoma.
Gao YW; Chen YX; Wang ZM; Zhou LD; Li XY; Li LX; Luo QZ; Tian W; Fu CY; Zhou JH
Hepatogastroenterology; 2008; 55(82-83):345-50. PubMed ID: 18613363
[TBL] [Abstract][Full Text] [Related]
50. Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact.
Barros MH; Hassan R; Niedobitek G
Clin Cancer Res; 2012 Jul; 18(14):3762-71. PubMed ID: 22645050
[TBL] [Abstract][Full Text] [Related]
51. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma.
Dorfman DM; Brown JA; Shahsafaei A; Freeman GJ
Am J Surg Pathol; 2006 Jul; 30(7):802-10. PubMed ID: 16819321
[TBL] [Abstract][Full Text] [Related]
52. Overexpression of CD7 in classical Hodgkin lymphoma-infiltrating T lymphocytes.
Seegmiller AC; Karandikar NJ; Kroft SH; McKenna RW; Xu Y
Cytometry B Clin Cytom; 2009 May; 76(3):169-74. PubMed ID: 18956470
[TBL] [Abstract][Full Text] [Related]
53. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy.
Alonso-Álvarez S; Vidriales MB; Caballero MD; Blanco O; Puig N; Martin A; Peñarrubia MJ; Zato E; Galende J; Bárez A; Alcoceba M; Orfão A; González M; García-Sanz R
Leuk Lymphoma; 2017 May; 58(5):1144-1152. PubMed ID: 27733075
[TBL] [Abstract][Full Text] [Related]
54. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.
Petersen RP; Campa MJ; Sperlazza J; Conlon D; Joshi MB; Harpole DH; Patz EF
Cancer; 2006 Dec; 107(12):2866-72. PubMed ID: 17099880
[TBL] [Abstract][Full Text] [Related]
55. MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis.
Hsi ED; Sup SJ; Alemany C; Tso E; Skacel M; Elson P; Alonso MA; Pohlman B
Am J Clin Pathol; 2006 May; 125(5):776-82. PubMed ID: 16707382
[TBL] [Abstract][Full Text] [Related]
56. CD44H and CD44V6 expression in different subtypes of Hodgkin lymphoma.
Anwar F; Wood BL
Mod Pathol; 2000 Oct; 13(10):1121-7. PubMed ID: 11048807
[TBL] [Abstract][Full Text] [Related]
57. [Pathology of Hodgkin's lymphoma].
Hansmann ML; Willenbrock K
Verh Dtsch Ges Pathol; 2003; 87():53-7. PubMed ID: 16888894
[TBL] [Abstract][Full Text] [Related]
58. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.
Ladoire S; Arnould L; Apetoh L; Coudert B; Martin F; Chauffert B; Fumoleau P; Ghiringhelli F
Clin Cancer Res; 2008 Apr; 14(8):2413-20. PubMed ID: 18413832
[TBL] [Abstract][Full Text] [Related]
59. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.
Badoual C; Hans S; Merillon N; Van Ryswick C; Ravel P; Benhamouda N; Levionnois E; Nizard M; Si-Mohamed A; Besnier N; Gey A; Rotem-Yehudar R; Pere H; Tran T; Guerin CL; Chauvat A; Dransart E; Alanio C; Albert S; Barry B; Sandoval F; Quintin-Colonna F; Bruneval P; Fridman WH; Lemoine FM; Oudard S; Johannes L; Olive D; Brasnu D; Tartour E
Cancer Res; 2013 Jan; 73(1):128-38. PubMed ID: 23135914
[TBL] [Abstract][Full Text] [Related]
60. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
